Lovenox Injection
NDC Package 0075-0621-61
Package Information
Lovenox (enoxaparin sodium) injection is enoxaparin is used to prevent and treat harmful blood clots. This formulation utilizes a injection delivery system. Marketed by Sanofi-aventis U.s. Llc, this product is identified by NDC 0075-0621 and is authorized under FDA application NDA020164.
Identification & Billing
- RxCUI: 854228 - enoxaparin sodium 30 MG in 0.3 ML Prefilled Syringe
- RxCUI: 854228 - 0.3 ML enoxaparin sodium 100 MG/ML Prefilled Syringe
- RxCUI: 854228 - 0.3 ML ENX sodium 100 MG/ML Prefilled Syringe
- RxCUI: 854228 - enoxaparin sodium 30 MG per 0.3 ML Prefilled Syringe
- RxCUI: 854232 - Lovenox 30 MG in 0.3 mL Prefilled Syringe
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0075 - Sanofi-aventis U.s. Llc
- 0075-0621 - Lovenox
- 0075-0621-61 - 10 SYRINGE in 1 CARTON / .6 mL in 1 SYRINGE
- 0075-0621 - Lovenox
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0075-0621). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0075-0621-61 identifies a specific commercial package of 10 syringe in 1 carton / .6 ml in 1 syringe of Lovenox, a human prescription drug labeled by Sanofi-aventis U.s. Llc. This injection is formulated for subcutaneous use and contains enoxaparin sodium as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Sanofi-aventis U.s. Llc on March 29, 1993. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
Enoxaparin is used to prevent and treat harmful blood clots. This helps to reduce the risk of a stroke or heart attack. This medication helps keep your blood flowing smoothly by lowering the activity of clotting proteins in the blood. Enoxaparin is an anticoagulant, also known as a "blood thinner." It is a type of heparin. Conditions which increase your risk of developing blood clots include certain types of surgeries (such as knee/hip replacement, abdominal), long periods of being immobile, certain types of heart attack, and a specific type of chest pain called unstable angina. For some medical conditions, enoxaparin may be used in combination with other "blood thinners."
How is this Sanofi-aventis U.s. Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00075062161. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.
